Mersana Therapeutics, Inc. – NASDAQ:MRSN
Mersana Therapeutics stock price today
$7.26
+5.75
+383.97%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Mersana Therapeutics stock price monthly change
-27.89%
month
Mersana Therapeutics stock price quarterly change
-27.89%
quarter
Mersana Therapeutics stock price yearly change
-34.21%
year
Mersana Therapeutics key metrics
Market Cap | 188.38M |
Enterprise value | 324.60M |
P/E | -1.8 |
EV/Sales | 12.21 |
EV/EBITDA | -1.62 |
Price/Sales | 15.69 |
Price/Book | 4.53 |
PEG ratio | -0.01 |
EPS | -1.14 |
Revenue | 38.29M |
EBITDA | -139.21M |
Income | -134.81M |
Revenue Q/Q | 18.49% |
Revenue Y/Y | 18.39% |
Profit margin | -768.26% |
Oper. margin | -766.59% |
Gross margin | 0% |
EBIT margin | -766.59% |
EBITDA margin | -363.51% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMersana Therapeutics stock price history
Mersana Therapeutics stock forecast
Mersana Therapeutics financial statements
| Jun 2023 | 10.65M | -54.30M | -509.73% |
|---|---|---|---|
| Sep 2023 | 7.69M | -41.65M | -541.13% |
| Dec 2023 | 10.70M | -19.54M | -182.64% |
| Mar 2024 | 9.24M | -19.30M | -208.83% |
| Oct 2025 | 8.33M | -22.66M | -272% |
|---|---|---|---|
| Dec 2025 | 8.66M | -26.30M | -303.57% |
| Mar 2026 | 6.90M | -23.94M | -346.54% |
| Jul 2026 | 6.66M | -20.98M | -314.92% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 311000000 | 221.2M | 71.13% |
|---|---|---|---|
| Sep 2023 | 262904000 | 210.70M | 80.15% |
| Dec 2023 | 226060000 | 189.15M | 83.68% |
| Mar 2024 | 198373000 | 170.38M | 85.89% |
| Jun 2023 | -61.83M | -5.43M | 73.18M |
|---|---|---|---|
| Sep 2023 | -46.08M | 103.77M | -146K |
| Dec 2023 | -34.14M | 20.14M | 92K |
| Mar 2024 | -32.65M | -72.54M | 5.82M |
Mersana Therapeutics alternative data
| Aug 2023 | 228 |
|---|---|
| Sep 2023 | 228 |
| Oct 2023 | 228 |
| Nov 2023 | 228 |
| Dec 2023 | 228 |
| Jan 2024 | 228 |
| Feb 2024 | 228 |
| Mar 2024 | 228 |
| Apr 2024 | 228 |
| May 2024 | 228 |
| Jun 2024 | 123 |
| Jul 2024 | 123 |
Mersana Therapeutics other data
100.00%
+3.70%
of MRSN is owned by hedge funds
152
+3
101.64M
+9.42M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 65329 |
| Sep 2024 | 0 | 50423 |
| Oct 2024 | 0 | 64848 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BALA MOHAN officer: SVP, Chief Development.. | Common Stock | 1,884 | $1.9 | $3,580 | ||
Option | BALA MOHAN officer: SVP, Chief Development.. | Common Stock | 6,250 | N/A | N/A | ||
Option | BALA MOHAN officer: SVP, Chief Development.. | Restricted Stock Unit | 6,250 | N/A | N/A | ||
Sale | DESCHUYTNER BRIAN officer: SVP, COO.. | Common Stock | 5,598 | $1.96 | $10,972 | ||
Sale | CARVAJAL ALEJANDRA officer: SVP, Chief Legal Officer | Common Stock | 5,598 | $1.96 | $10,972 | ||
Sale | BALA MOHAN officer: SVP, Chief Development.. | Common Stock | 5,598 | $1.96 | $10,972 | ||
Sale | MANDELIA ASHISH officer: VP, Chief Accounting O.. | Common Stock | 3,361 | $1.96 | $6,588 | ||
Sale | LOWINGER TIMOTHY B officer: SVP, Chi.. | Common Stock | 5,598 | $1.96 | $10,972 | ||
Sale | DESCHUYTNER BRIAN officer: SVP, COO.. | Common Stock | 8,089 | $2 | $16,178 | ||
Sale | CARVAJAL ALEJANDRA officer: SVP, Chief Legal Officer | Common Stock | 8,089 | $2 | $16,178 |
| Patent |
|---|
Application Filling date: 4 Jan 2022 Issue date: 28 Jul 2022 |
Application Filling date: 9 Sep 2021 Issue date: 3 Mar 2022 |
Grant Filling date: 31 Jul 2020 Issue date: 26 Oct 2021 |
Grant Filling date: 21 Nov 2017 Issue date: 5 Oct 2021 |
Application Filling date: 20 Jan 2021 Issue date: 30 Sep 2021 |
Application Filling date: 8 Jan 2021 Issue date: 22 Jul 2021 |
Application Filling date: 23 Jan 2020 Issue date: 15 Apr 2021 |
Grant Filling date: 13 Mar 2017 Issue date: 16 Mar 2021 |
Application Filling date: 31 Jul 2020 Issue date: 4 Feb 2021 |
Grant Filling date: 22 Jun 2018 Issue date: 15 Sep 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q1 2023 9 May 2023 | Q1 2023 Earnings Call Transcript |
Intellia Therapeutics: The Future Is Here
bluebird bio: A Risk Worth Taking
Mersana Therapeutics: Unrecognized Promise In UpRi's Cancer Fight
Mersana: I Like The Science, Derisking Will Come From More Proof
AstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet)
ImmunoGen Needs To Make The Most Of Its First-Mover Opportunity
Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
What's the price of Mersana Therapeutics stock today?
One share of Mersana Therapeutics stock can currently be purchased for approximately $7.26.
-
When is Mersana Therapeutics's next earnings date?
Unfortunately, Mersana Therapeutics's (MRSN) next earnings date is currently unknown.
-
Does Mersana Therapeutics pay dividends?
No, Mersana Therapeutics does not pay dividends.
-
How much money does Mersana Therapeutics make?
Mersana Therapeutics has a market capitalization of 188.38M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 38.65% to 36.86M US dollars.
-
What is Mersana Therapeutics's stock symbol?
Mersana Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "MRSN".
-
What is Mersana Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Mersana Therapeutics?
Shares of Mersana Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Mersana Therapeutics's key executives?
Mersana Therapeutics's management team includes the following people:
- Ms. Anna Protopapas Pres, Chief Executive Officer & Director(age: 61, pay: $881,500)
- Dr. Timothy B. Lowinger Chief Science & Technology Officer(age: 61, pay: $606,130)
- Mr. Brian C. DeSchuytner Senior Vice President & Chief Financial Officer(age: 47, pay: $580,010)
- Dr. Arvin Yang M.D., Ph.D. Senior Vice President & Chief Medical Officer(age: 49, pay: $533,540)
-
How many employees does Mersana Therapeutics have?
As Jul 2024, Mersana Therapeutics employs 123 workers, which is 46% less then previous quarter.
-
When Mersana Therapeutics went public?
Mersana Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 28 Jun 2017.
-
What is Mersana Therapeutics's official website?
The official website for Mersana Therapeutics is mersana.com.
-
Where are Mersana Therapeutics's headquarters?
Mersana Therapeutics is headquartered at 840 Memorial Drive, Cambridge, MA.
-
How can i contact Mersana Therapeutics?
Mersana Therapeutics's mailing address is 840 Memorial Drive, Cambridge, MA and company can be reached via phone at +61 74980020.
Mersana Therapeutics company profile:
Mersana Therapeutics, Inc.
mersana.comExchange:
NASDAQ
Full time employees:
123
Industry:
Biotechnology
Sector:
Healthcare
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
840 Memorial Drive
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001442836
ISIN: US59045L1061
CUSIP: 59045L106
